Medications development is a high priority program at National Institute on Alcohol Abuse and Alcoholism (NIAAA). Currently, only three medications are approved by the Food and Drug Administration (FDA) for the treatment of alcohol use disorder (AUD). These medications have demonstrated small to moderate effect sizes in clinical trials and do not work for everyone, making the search for new molecular targets and more efficacious pharmacotherapies critical. The purpose of the current contract is to support a Contract Research Organization (CRO) to conduct all aspects of multiple, multi-center, pharmacotherapy clinical trials for the treatment of AUD.